福瑞股份收盘下跌1.20%，滚动市盈率81.84倍，总市值81.19亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Furuya Co., which operates in the medical device industry, specifically focusing on liver disease-related products and services [1][2] - As of May 19, Furuya Co. closed at 30.48 yuan, with a decline of 1.20%, resulting in a rolling price-to-earnings (PE) ratio of 81.84 times, significantly higher than the industry average of 49.26 times and the median of 36.71 times [1][2] - The total market capitalization of Furuya Co. is reported at 8.119 billion yuan, ranking it 102nd in the industry based on PE ratio [1][2] Group 2 - For the first quarter of 2025, Furuya Co. reported a revenue of 330 million yuan, reflecting a year-on-year increase of 2.35%, while the net profit was 28.637 million yuan, showing a decline of 32.97% compared to the previous year [1] - The gross profit margin for Furuya Co. stands at 76.76%, indicating a strong profitability despite the drop in net profit [1] - As of the first quarter of 2025, 18 institutions hold shares in Furuya Co., including 14 funds, 3 other entities, and 1 insurance company, with a total holding of 49.9011 million shares valued at 1.593 billion yuan [1]